CAS 167305-00-2

Omapatrilat

Description:

Omapatrilat is a pharmaceutical compound primarily known for its role as an antihypertensive agent. It functions as a dual inhibitor of angiotensin-converting enzyme (ACE) and neprilysin, which are key enzymes involved in the regulation of blood pressure and fluid balance. By inhibiting these enzymes, Omapatrilat promotes vasodilation and reduces blood pressure. The compound is characterized by its complex molecular structure, which includes various functional groups that contribute to its biological activity. Omapatrilat has been studied for its potential benefits in treating conditions such as hypertension and heart failure. However, its development has faced challenges, particularly concerning side effects, including angioedema, which has limited its clinical use. The substance is typically administered in a controlled dosage, and its pharmacokinetics involve absorption, distribution, metabolism, and excretion processes that are crucial for its therapeutic efficacy. Overall, Omapatrilat represents an important area of research in cardiovascular pharmacology, highlighting the ongoing efforts to develop effective treatments for hypertension and related disorders.

Formula: C₁₉H₂₄N₂O₄S₂

InChI: InChI=1S/C19H24N2O4S2/c22-17(15(26)11-12-5-2-1-3-6-12)20-13-9-10-27-16-8-4-7-14(19(24)25)21(16)18(13)23/h1-3,5-6,13-16,26H,4,7-11H2,(H,20,22)(H,24,25)/t13-,14-,15-,16-/m0/s1

InChI key: InChIKey=LVRLSYPNFFBYCZ-VGWMRTNUSA-N

SMILES: C(O)(=O)[C@H]1N2[C@](CCC1)(SCC[C@H](NC([C@H](CC3=CC=CC=C3)S)=O)C2=O)[H]

Synonyms:

• (4S,7S,10aS)-5-oxo-4-{[(2S)-3-phenyl-2-sulfanylpropanoyl]amino}octahydro-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid
• (4S,7S,10aS)-Octahydro-4-[[(2S)-2-mercapto-1-oxo-3-phenylpropyl]amino]-5-oxo-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid
• (7S,10aS)-5-oxo-4-{[(2S)-3-phenyl-2-sulfanylpropanoyl]amino}octahydro-7H-pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid
• 7H-Pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid, octahydro-4-[(2-mercapto-1-oxo-3-phenylpropyl)amino]-5-oxo-, [4S-[4α(R*),7α,10aβ]]-
• 7H-Pyrido[2,1-b][1,3]thiazepine-7-carboxylic acid, octahydro-4-[[(2S)-2-mercapto-1-oxo-3-phenylpropyl]amino]-5-oxo-, (4S,7S,10aS)-
• Bms 186716
• Bms 186716-01
• Omapatrilat/Vanlev
• Vanlev
• Omapatrilat

Omapatrilat

CAS: 167305-00-2

Formula: C₃₈H₄₇N₄O₈S₄

Purity: 99.88%

Color and Shape: Solid

Molecular weight: 816.0618

Ref: IN-DA00AOX7

Omapatrilat

CAS: 167305-00-2

Omapatrilat is a vasopeptidase inhibitor that is used in the treatment of gastrointestinal diseases. It has been shown to lower blood pressure and reduce the risk of stroke, heart attack, and cardiovascular death in people with hypertension and/or coronary artery disease. Omapatrilat blocks the degradation of natriuretic peptides by inhibiting vasopeptidases that break down atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP). This leads to an increase of ANP and BNP levels, which causes a reduction in blood pressure. The effect on blood pressure can be monitored using invasive or non-invasive methods. A dosage range of 10–40 mg per day has been shown to be effective for lowering blood pressure.

Formula: C₁₉H₂₄N₂O₄S₂

Purity: Min. 95%

Molecular weight: 408.54 g/mol

Ref: 3D-SGA30500

Omapatrilat

CAS: 167305-00-2

Omapatrilat is an orally active dual inhibitor of ACE and NEP (neprilysin), with Ki values of 0.64 and 0.45 nM, respectively, suppressing induced hypotension.

Formula: C₁₉H₂₄N₂O₄S₂

Purity: 98.87%

Color and Shape: Solid

Molecular weight: 408.53

Ref: TM-T16385